Targeting cancer treatment to reduce side effects
Official title: Antigen-targeted activation of Topo1 inhibitors via click chemistry
Funded at Shasqi, INC. · NIH-11007506 · Data updated 2026-11-12
This study is looking at a new way to make cancer treatment better by using a special method to deliver medicine directly to tumors, which could help reduce side effects and make the treatment more effective for patients.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Shasqi, INC. NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | September 6, 2024 |
| Project end | August 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $1,568,070 |
| NIH project number | 1R44CA291345-01A1 |
| Project ID | NIH-11007506 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research would be patients diagnosed with cancers that are currently treated with Topo1 inhibitors and who experience significant side effects from conventional therapies.
✕Less likely to help
Patients with cancers that do not respond to Topo1 inhibitors or those who are not eligible for chemotherapy may not benefit from this research.
What this research studies
This research focuses on improving cancer treatment by using a method called click chemistry to specifically activate Topo1 inhibitors at the site of tumors. By targeting the drugs directly to the cancer cells, the goal is to minimize the toxic side effects that often occur with traditional chemotherapy. Patients may benefit from a more effective treatment that reduces the need for high doses and lowers the risk of adverse drug effects. The approach aims to enhance the delivery and efficacy of existing cancer therapies.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments with fewer side effects for patients.
How similar studies have gone: Previous research has shown promise in using targeted therapies to improve cancer treatment outcomes, suggesting that this approach may be effective.
Where this research is happening
-
Shasqi, INC.
San Francisco, United States Active
Researchers
- Principal investigator: Mejia Oneto, Jose M — Shasqi, INC.
- Study coordinator: Mejia Oneto, Jose M
Related research
Other NIH-funded projects on the same topics.
-
CEACAM5-targeted click-activated cancer drugs
A new approach uses a two-part system to activate chemotherapy only at the tumor, aiming to boost effectiveness and reduce side effects for people with cancer.
-
Turning on chemotherapy at tumors with targeted click chemistry
This project develops a way to activate powerful Topo1 chemotherapy drugs only at tumor sites so people with cancer may get stronger treatment with fewer side effects.
-
Targeted drug activation to improve cancer treatment
This study is testing a new way to deliver medicine that targets the disease directly, which could help you feel better while causing fewer side effects.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.